Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXB750 dose-finding study in symptomatic heart failure with reduced or mildly reduced ejection fraction
NL-OMON58887Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of xxb750 in heart failure (HF) (4 arms), sponsored by Novartis. Primary endpoint: Change in log NT-proBNP from baseline to Week 16. Started May 2024; status: completed.
02
Drugs
xxb750
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON58887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58887.